Clinical trials: Spinal and Bulbar Muscular Atrophy (SBMA)
D011471, D064129
CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION
Observational prospective study investigating the plasmatic levels of miRNA according to AR-V7 mutational status in mCRPC patients receiving standard of care therapy.
- Conditions
- D011471, D064129, D035683, D009360
- Trial name
- PRIMERA (NCT04188275)
- Testing
- Periodic ARV7 and miRNA evaluation
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DESCRIPTION: Prostate cancer (PC) patients receive androgen deprivation…
- Trial name
- PHAROS (NCT06705686)
- Testing
- (R)-9bMS
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- TechnoGenesys, Inc.
Hyperandrogenism, Polycystic Ovary Syndrome
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism, androgen-receptor blockade (spironolactone) improves the ability of progesterone to acutely reduce waking luteinizing hormone…
- Conditions
- Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
- Trial name
- CRM008 (NCT03068910)
- Testing
- Micronized progesterone, Spironolactone
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Advanced Prostate Carcinoma
Physical Function During ARSI Treatment
This single arm observational pilot study aims to determine the longitudinal effects of androgen receptor signaling inhibitors (ARSI) in men with advanced prostate cancer.
- Trial name
- NCT05612880
- Testing
- androgen receptor signaling inhibitors
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
BRCA1 Mutation, High-grade Serous Ovarian Cancer
Breast Cancer BRCA1 Carriers: a Pilot Study
The purpose of this study is to examine how a single dose of MIFEPREX® (mifepristone) affects the breast tissue in patients with BRCA1 (a gene that normally acts to restrain the growth of cells in the breast, but if it mutates…
- Conditions
- BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05062174
- Testing
- Mifepristone 200 MG, Prophylactic mastectomy
- Where
- 2 sites in United States
- Sponsor
- Indiana University
Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency
AR, IGF-IR, IR and Peripheral Artery Disease
Peripheral artery Disease (PAD) is a major cardiovascular disease that can impair quality of life (QoL). It affects more often male patients and its pathophysiology is not completely known.
- Conditions
- Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency, Insulin Receptor, Defect in
- Trial name
- ANIMALPAD (NCT04710186)
- Testing
- arterial reconstructive open surgery
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Catanzaro
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate…
- Trial name
- NCT02949284
- Testing
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Rutgers, The State University of New Jersey